DocuSign (DOCU) Could Be 16% Undervalued Following The Software Rally

DocuSign (DOCU) jumped 5.6% on July 24, 2026, as part of a broad rally in software stocks. This move gave investors fresh reason to reassess how the stock fits into current sector trends.

See our latest analysis for DocuSign.

For context, DocuSign’s 14.01% 1 month share price return and 9.13% 3 month share price return contrast with a year to date share price decline of 22.22% and a 1 year total shareholder return decline of 36.85%. This points to short term momentum but a still weak longer term record.

If this rebound in DocuSign has you looking across the software space, it could be a useful time to broaden your watchlist with 65 profitable AI stocks that aren't just burning cash

After a sharp one day jump and a mixed track record over the past year, the question for DocuSign is simple: lean into the rebound now, or wait for a pullback that brings the valuation closer to your comfort zone?

Advertisement

Most Popular Narrative: 16.2% Undervalued

With DocuSign closing at $50.44 against a narrative fair value of $60.16, the current price sits below what this widely followed framework suggests.

Sustained adoption of digital workflows across global industries and increased prevalence of remote/hybrid work environments is driving persistent demand for eSignature, contract lifecycle management (CLM), and AI-powered agreement management (IAM) solutions. This is reflected in accelerating direct sales, healthy new bookings, and improving renewal rates, providing strong ongoing support for revenue and billings growth.

Read the complete narrative.

Curious what justifies that higher fair value for DocuSign? The narrative leans on compounding revenue, expanding margins, and a future earnings multiple that assumes meaningful execution. The exact mix of those inputs may surprise you.

Result: Fair Value of $60.16 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this DocuSign narrative can quickly look different if core eSignature growth slows further, or if competition and AI tools pressure pricing and renewal rates.

Find out about the key risks to this DocuSign narrative.

Another View: What DocuSign’s P/E Is Telling You

While the narrative fair value for DocuSign points to undervaluation, the P/E picture is less comfortable. At 30.6x, the stock trades above the US software average of 27.8x and above a fair ratio of 28.9x, which implies less room for error if expectations slip.

That gap between today’s pricing and the fair ratio may reflect confidence in DocuSign’s agreement platform, but it also raises the question of how much optimism is already in the share price, and how you would feel if growth or margins track closer to the sector average instead.

See what the numbers say about this price — find out in our valuation breakdown.

NasdaqGS:DOCU P/E Ratio as at Jul 2026
NasdaqGS:DOCU P/E Ratio as at Jul 2026

Next Steps

Seeing both optimism and caution around DocuSign, it makes sense to move quickly, review the underlying data for yourself, and decide where you stand. To weigh those mixed signals in one place, take a closer look at the 2 key rewards and 1 important warning sign

Looking for more investment ideas beyond DocuSign?

If DocuSign has sharpened your focus, do not stop there. Spread your attention across other opportunities that match your risk tolerance and income goals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NasdaqGS:DOCU

DocuSign

Provides electronic signature solution in the United States and internationally.

Excellent balance sheet and fair value.

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1157.5% undervalued
37 users have followed this narrative
2 users have commented on this narrative
6 users have liked this narrative
WE
WealthAP
NOVO B logo
WealthAP on Novo Nordisk ·

Novo Nordisk (NVO): Is the "Easy Growth" Story Over?

Fair Value:DKK 407.7721.4% undervalued
59 users have followed this narrative
0 users have commented on this narrative
7 users have liked this narrative
VA
ValueInvestingSubstack
ZTS logo
ValueInvestingSubstack on Zoetis ·

Zoetis down -50% over the past year

Fair Value:US$92.9218.9% undervalued
21 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative
CE
CentryResearch
LEU logo
CentryResearch on Centrus Energy ·

Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.

Fair Value:US$19013.7% undervalued
19 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative

Updated Narratives

AE
ASML logo
Aequitas on ASML Holding ·

ASML Will Reign as the Kingpin of the Semiconductor Supply Chain

Fair Value:€1.87k16.5% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AE
FTNT logo
Aequitas on Fortinet ·

Fortinet, compounding Cyber Security Player.

Fair Value:US$116.8430.4% overvalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AE
CSU logo
Aequitas on Constellation Software ·

Constellation Software: A Proven Serial Acquirer at a Discount

Fair Value:CA$3.72k28.3% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.6% undervalued
70 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative
CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.919.1% undervalued
71 users have followed this narrative
0 users have commented on this narrative
5 users have liked this narrative
TR
tripledub
GOOGL logo
tripledub on Alphabet ·

Warren Buffett Just Bet $10 Billion on Google. The Catch? You May Already Be Too Late.

Fair Value:US$23039.0% overvalued
93 users have followed this narrative
1 users have commented on this narrative
18 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

0
|
0